{"organizations": [], "uuid": "a2137444ed7aed5d6ae2d6d36b8bd588975f25ad", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180507.html", "section_title": "Archive News &amp; Video for Monday, 07 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-macrogenics-posts-qtrly-net-loss-p/brief-macrogenics-posts-qtrly-net-loss-per-common-share-of-1-34-idUSASC0A05F", "country": "US", "domain_rank": 408, "title": "MacroGenics Posts Qtrly Net Loss Per Common Share Of $1.34", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.292, "site_type": "news", "published": "2018-05-08T04:44:00.000+03:00", "replies_count": 0, "uuid": "a2137444ed7aed5d6ae2d6d36b8bd588975f25ad"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-macrogenics-posts-qtrly-net-loss-p/brief-macrogenics-posts-qtrly-net-loss-per-common-share-of-1-34-idUSASC0A05F", "ord_in_thread": 0, "title": "MacroGenics Posts Qtrly Net Loss Per Common Share Of $1.34", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "macrogenics inc", "sentiment": "negative"}, {"name": "aml", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 7 (Reuters) - MacroGenics Inc:\n* MACROGENICS PROVIDES UPDATE ON CORPORATE PROGRESS AND 1ST QUARTER 2018 FINANCIAL RESULTS\n* MACROGENICS - IN H2, SEES TO PROVIDE CLINICAL UPDATES ON FLOTETUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY AML, ON COMBINATION OF ENOBLITUZUMAB WITH ANTI-PD-1 AGENT\n* ANTICIPATE TWO OF CO’S ONCOLOGY PRODUCT CANDIDATES WILL MOVE INTO CLINICAL PIPELINE THIS YEAR\n* TOTAL REVENUE WAS $4.7 MILLION FOR QUARTER ENDED MARCH 31, 2018, COMPARED TO $2.1 MILLION\n* QTRLY NET LOSS PER COMMON SHARE $1.34 * Q1 EARNINGS PER SHARE VIEW $-1.08, REVENUE VIEW $6.8 MILLION — THOMSON REUTERS I/B/E/S Source text for Eikon:\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-08T04:44:00.000+03:00", "crawled": "2018-05-08T16:43:32.011+03:00", "highlightTitle": ""}